Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2014-09-24 Report Publication Anno…
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 99% confidence The document is titled "Mise à disposition du rapport financier semestriel 2014" (Making available of the 2014 semi-annual financial report). It explicitly states that the semi-annual financial report for the period ending June 30, 2014, has been made available to the public and filed with the AMF (Autorité des Marchés Financiers). The document itself is very short (2083 characters) and serves primarily to announce the availability of the actual report, rather than containing the full financial details of the report itself. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, especially when the actual report is referenced as being attached or available elsewhere. It is not the comprehensive Interim Report (IR) itself, but the announcement of its publication.
2014-09-24 French
Communiqués au titre de l'obligation d'information permanente / Communiqué sur comptes, résultats, chiffres d’affaires
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive report detailing the financial results for the first half of 2014 (semestriels consolidés clos au 30 juin 2014). It includes a balance sheet table, management commentary on financial performance, business highlights, and future outlook. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2014
2014-09-23 French
Communicated under the obligation to provide permanent information / Communication relating to accounts, results, and turnover
Earnings Release Classification · 99% confidence The document explicitly states that it reports 'consolidated half-year results at the end of June 30th, 2014'. It contains detailed financial tables (Sales, Operating profit/loss, Net profit/loss) comparing H1 2014 to H1 2013, management commentary on the period, and highlights of operational activity for the first half of the year. This content structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it is a detailed report, not just the initial highlights announcement, and it is not an Annual Report (10-K) because it covers only six months. H1 2014
2014-09-23 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated September 3, 2014, announcing that THERADIAG is advancing the second phase of its microRNA diagnostic kit study for rectal cancer (project miCRA). It details research progress, partnerships (ICM), market potential, and provides background information on the disease and the company. This type of announcement, detailing operational progress, research milestones, and strategic updates, is characteristic of a general corporate communication that doesn't fit the specific financial reporting categories (like 10-K, ER, IR) or specific corporate actions (like DIV, CAP, DIRS). Since it is a general update on business/research progress and not a formal regulatory filing like a 10-K or a specific financial release like an Earnings Release (ER), it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format, RNS is the most appropriate fallback for non-standard, material corporate news.
2014-09-03 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated September 3, 2014, announcing a specific operational update: the launch of the second phase of the miCRA study for rectal cancer theranostics. It details research progress, partnerships (ICM), and market potential. This type of announcement, focusing on business development, research milestones, or operational updates rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under general regulatory announcements or investor news. Since it is not a formal financial report, a transcript, or a specific corporate action like a dividend or share issue, it best fits the 'Regulatory Filings' (RNS) category as a general corporate disclosure, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format, RNS is the most appropriate general disclosure category.
2014-09-03 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references the French Commercial Code and the AMF (Autorité des Marchés Financiers) regulations. The core content is a table showing the total number of shares and voting rights as of a specific date (August 31, 2014). This type of mandatory disclosure regarding the total share count and voting power directly relates to the company's capital structure and ownership changes, which aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a direct publication, it is not a general regulatory filing (RNS) or a report announcement (RPA), but a specific disclosure about the capital base.
2014-09-02 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.